Conditions: Neoplasms, Gastrointestinal Tract
Keywords: c-Met Metastatic Gastric Carcinoma adenocarcinoma Gastric cancer GSK1363089 XL880 MET inhibitor
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 74
Healthy volunteers: no

Brief summary:
This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric carcinoma.

Detailed description:

Arms:
arm 1: Dosing for first 5 days in every 14-day period. arm 2: dosed every day

Interventions: intervention 1: GSK1363089 (formerly XL880)
Intervention descriptions: intervention 1: c-MET tyrosine kinase inhibitor

Protocol document: